# GLP-1 dose escalation: why you start low and step up, and what each label says > Why do Ozempic, Wegovy, Mounjaro and Zepbound start at a low dose and increase over months? The FDA labels build in a step-up schedule for one reason — to reduce nausea and GI side effects. Here's how titration works and why it's a prescriber's decision, not a self-dosing plan. **Evidence grade:** Established (rung 1 of 8 on the Peptide Evidence Ladder) · **Last reviewed:** 2026-07-20 · **Source page:** https://thepeptideera.com/evidence/glp1-dosing-and-titration ## Short answer GLP-1 medicines (Ozempic, Wegovy, Mounjaro, Zepbound) are started at a low dose and increased in steps over several months because their FDA labels build in that escalation for one stated reason: to reduce gastrointestinal side effects like nausea. Each label defines a starting dose that is a tolerance-building "runway," not a treatment target, then a series of higher steps held for a minimum interval (generally at least four weeks) before any increase — and the labels describe increases as individualized and prescriber-directed. This page explains why that gradual approach works and reports what the approved labels say; it is not medical advice or a dosing schedule to follow on your own. Your actual dose and timing are a decision for the clinician who prescribes it. ## Key takeaways - The dose starts low on purpose. The Ozempic, Mounjaro and Zepbound labels each say to "follow the dosage escalation … to reduce the risk of gastrointestinal adverse reactions" (Wegovy's label says the same in near-identical words — to "minimize" them). The low starting dose — 0.25 mg for semaglutide, 2.5 mg for tirzepatide — is an initiation dose, not the dose that does the therapeutic work: it's a runway that lets your body adapt. - Why gradual works: these drugs slow stomach emptying and act on nausea and appetite pathways, and the gut adapts over weeks. Stepping the dose up slowly lets that tolerance build, which blunts the nausea, vomiting and diarrhea a full dose would otherwise provoke. In the pivotal weight trial, GI events were the most common side effect and mostly transient and mild-to-moderate. - Each step is held for a minimum interval — generally at least 4 weeks — before any increase, and the labels frame increases conditionally ("if additional control is needed") and as a prescriber's call. The full maintenance dose typically isn't reached until roughly month 4–5. This is a described structure, not a schedule to self-administer. - Rushing or skipping steps tends to backfire. Because the whole escalation exists to control GI reactions, compressing it removes the buffer that builds tolerance and raises the risk of nausea, vomiting and dehydration. After a long gap in treatment, prescribers often re-start lower and re-titrate — a clinical judgment, not something to improvise. - Your dose is individualized. The labels write dose changes as decided with your prescriber, based on how you respond and tolerate it. Compounded or "research" semaglutide/tirzepatide sold for self-dosing is not FDA-approved and carries no verified titration schedule. Whatever you read here, the numbers are a label reference — not a plan to run yourself. ## Safety essentials worth knowing These apply to GLP-1 and dual/triple-agonist medicines generally. They’re label-level points, not the full list, and not advice about you — your prescriber and the FDA label are the authority. - **Pregnancy & breastfeeding:** these medicines are not recommended in pregnancy, and intentional weight loss is generally not advised in pregnancy; the labels advise stopping before a planned pregnancy. Breastfeeding status is a conversation to have with your clinician. - **Birth control:** some of these medicines (such as tirzepatide) can make *oral* contraception less reliable. If you could become pregnant, ask about backup or non-oral contraception. - **Thyroid boxed warning:** this drug class carries an FDA boxed warning (thyroid C-cell tumours seen in rodents) and is not for people with a personal or family history of medullary thyroid cancer (MTC) or MEN 2. - **Blood sugar:** combined with insulin or a sulfonylurea, these medicines can cause low blood sugar — those other medicines often need prescriber-managed adjustment, not self-adjustment. - **Eating disorders:** an appetite-suppressing medicine warrants particular caution with a current or past eating disorder; disclose this to your clinician. - **Surgery, sedation & endoscopy:** because these medicines slow stomach emptying, tell your surgical or anaesthesia team you take a GLP-1 well in advance — they'll decide with you whether to continue or hold it (more: https://thepeptideera.com/evidence/glp1-and-surgery). Type "Ozempic dose schedule" or "how much semaglutide should I take" into a search bar and you'll find a lot of clean-looking ladders — week 1 this many milligrams, week 5 that many — often sitting right next to a link to buy the drug. That's the wrong way to read a dose. The schedule on an approved label isn't a target to sprint toward; it's a **deliberately slow on-ramp**, and understanding *why* it's slow is more useful than any number on a chart. This page explains how dose escalation — "titration" — works on these medicines, and reports what the FDA labels actually say. It is **not medical advice, and not a schedule to follow on your own**. Your dose and its timing are decided with the clinician who prescribes it. ## Why the dose starts low and goes up slowly GLP-1 (and, for tirzepatide, GLP-1/GIP) receptor agonists do part of their job by **slowing how fast the stomach empties** and acting on the brain's appetite and nausea pathways. That's also why the most common side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation. The good news is that the gut largely **adapts** to these effects over a few weeks. Titration is built around that adaptation. The approach begins at a dose too low to do much therapeutically, holds it while the body adapts, then steps up — and repeats. The FDA labels for these medicines state the reason in nearly identical words: **"Follow the dosage escalation … to reduce the risk of gastrointestinal adverse reactions"** (Wegovy's says "to minimize" them). In the pivotal weight-loss trial (STEP 1), the researchers built in a fixed 16-week escalation to minimize gastrointestinal side effects, and reported that those events, while common, were **mostly transient and mild to moderate.** The starting dose is a runway, not a destination. The labels are explicit that the lowest dose is an initiation dose. Mounjaro's, for example, says its 2.5 mg dose is "for treatment initiation and is not intended for glycemic control," and Zepbound's calls its 2.5 mg dose one that is "not approved as a maintenance dosage." On the semaglutide side, Ozempic's label lists 0.25 mg as the initiation dose and reserves the higher steps for glycemic control. Its whole job is to build tolerance before the doses that actually do the work. ## What the approved labels describe Read this as a **description of how the labels are shaped — not a plan to self-administer**. The specific milligram at each step is defined by the label and applied by a prescriber; it is not a sequence to run yourself. - **Semaglutide** (Ozempic, Wegovy) begins at a low starting dose and is raised over roughly monthly intervals across several months before a maintenance dose is reached. Wegovy's weight-management label describes about five escalation steps over roughly four months; Ozempic's diabetes label raises the dose only conditionally, "if additional glycemic control is needed." - **Tirzepatide** (Mounjaro, Zepbound) likewise begins at a low starting dose and is stepped up no sooner than about monthly toward a maintenance dose, up to a labeled maximum — each increase a prescriber's decision. Three principles run through all of them, and they matter more than the specific milligrams: (1) a defined **starting dose that is a runway**, not a therapeutic target; (2) a **minimum interval** — generally at least four weeks — before any step up; and (3) increases that are **conditional and prescriber-directed** ("may be increased," not "will be increased"). ## Why rushing or skipping steps backfires If the entire point of the schedule is to control GI reactions, then compressing it — jumping a step, or bumping the dose early because progress feels slow — removes the buffer that builds tolerance. The predictable result is more nausea, more vomiting, and the dehydration that can follow. "Faster" is not "better" here; it's usually just "sicker," and it's one reason self-directed dosing from non-prescribed sources — which may also be unsafe or unlawful to obtain — is risky. When to get help. Seek prompt medical care if you can't keep fluids down, notice signs of dehydration (marked dizziness, dark urine, little or no urination), or have severe or persistent abdominal pain — especially pain that radiates through to the back with vomiting, which is not expected titration nausea and can be a sign of pancreatitis. Persistent vomiting can lead to dehydration and, uncommonly, kidney injury. The labels also allow the schedule to **bend the other way**: the weight-management labels describe delaying an increase — or dropping back a step — if a dose isn't tolerated, again as a decision made with a prescriber. Titration is a two-way dial, not a one-way climb. ## Missed doses and long gaps A single missed weekly dose isn't an emergency, and each label gives its own rule for it — and they differ even between two versions of the same drug. (We cover the specifics on the [missed-dose page](/evidence/glp1-missed-dose): Ozempic within 5 days, Wegovy keyed to whether your next dose is more than 2 days away, Mounjaro and Zepbound within 4 days.) The key principle is that none of the labels have you **double up** to catch up. A longer gap is different. Because tolerance to the GI effects fades when you stop, restarting at your old higher dose can bring the early nausea back. After a prolonged break, prescribers commonly **re-initiate lower and re-titrate** — but exactly how is a clinical judgment for your prescriber, not something to improvise from a web page. ## The honest bottom line Dose escalation on these medicines is one of the best-established things about them: four independent FDA labels and the pivotal trial program all build in the same slow step-up for the same reason — to make the drugs tolerable while your body adapts. What that means for *you* — which dose, how fast, whether to pause a step — is individualized and belongs with the clinician who prescribes and monitors it. Treat any clean "just follow this schedule" chart, especially one attached to a place selling the drug, as the tell of a page that's skipped the part that actually keeps you safe. ## Frequently asked questions **Why do you start Ozempic at 0.25 mg if it doesn't cause much weight loss?** Because that low dose is a **starting dose, not a treatment dose** — the label lists 0.25 mg as the initiation dose and reserves the higher steps for glycemic control. Its purpose is to let your body adapt to the drug's effect on the stomach so that the later, effective doses cause less nausea. It's a runway, not the flight. **How long does it take to reach the full dose?** It depends on the medicine and is decided with your prescriber, but the labels build in a step roughly every four weeks. For semaglutide, the label's escalation reaches the maintenance dose at around month four; tirzepatide is stepped up no sooner than about every four weeks toward its maintenance dose. This describes the label structure — the exact milligrams and timing are the label's and your prescriber's, not a schedule to run yourself. **What happens if you increase the dose too fast?** The escalation exists precisely to limit gastrointestinal side effects, so moving faster than the label's minimum intervals tends to bring **more nausea, vomiting and diarrhea**, and the dehydration that can follow. It generally doesn't speed up results — it just makes the ramp harder to tolerate. Dose changes are a prescriber's decision. **Can I follow one of the dose charts I found online?** No — a dose chart isn't a substitute for a prescription. The numbers on the approved labels are individualized by a clinician who knows your history, your response and your other medicines, and the labels write every increase as a decision made with a prescriber. This is especially important given that compounded or "research" semaglutide and tirzepatide sold for self-dosing are **not FDA-approved** and come with no verified schedule. This page is educational, not a dosing recommendation. **Do I need to re-titrate if I stopped for a while?** Possibly — tolerance to the GI effects fades when you stop, so restarting at a previous higher dose can bring the early side effects back. Prescribers often restart lower and step back up, but the specifics are a clinical decision. Check with your prescriber or pharmacist before restarting after a gap. ## Sources (5) 1. Ozempic (semaglutide) — FDA Prescribing Information via DailyMed (§2 Dosage & Administration: initiate 0.25 mg weekly ×4 weeks as a starting dose 'not for glycemic control'; escalate ≥4 weeks per step; 'follow the dosage escalation … to reduce the risk of gastrointestinal adverse reactions'). — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79 [LABEL] 2. Wegovy (semaglutide) — FDA Prescribing Information via DailyMed (§2, Table 1: 16-week escalation across about five monthly steps to a 2.4 mg maintenance dose, to minimize GI reactions). — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b [LABEL] 3. Mounjaro (tirzepatide) — FDA Prescribing Information via DailyMed (§2: initiate 2.5 mg weekly ×4 weeks 'for treatment initiation … not for glycemic control'; increase in 2.5 mg increments after ≥4 weeks; max 15 mg). — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0 [LABEL] 4. Zepbound (tirzepatide) — FDA Prescribing Information via DailyMed (§2: initiate 2.5 mg ×4 weeks; increase in 2.5 mg increments after ≥4 weeks; maintenance 5/10/15 mg; 2.5 mg is not a maintenance dose). — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b [LABEL] 5. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989–1002. (68-week trial with a fixed 16-week dose escalation designed to minimize gastrointestinal adverse events; GI events most common, mostly transient and mild-to-moderate.) — https://www.nejm.org/doi/full/10.1056/NEJMoa2032183 [RCT] --- From The Peptide Era (https://thepeptideera.com) — evidence-graded, primary-sourced answers about GLP-1 medicines. Education, not medical advice. No doses, no sourcing.